Moxifalon T (Moxifloxacin)

Moxifloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV, making it useful for treating a range of respiratory and skin infections.

• Community‑acquired bacterial pneumonia: provides clinical improvement and bacterial clearance in adult patients.
• Acute bacterial sinusitis: reduces symptoms and eliminates the causative pathogens.
• Acute bacterial exacerbation of chronic bronchitis: shortens the duration of exacerbation and improves lung function.
• Skin and soft‑tissue infections: achieves resolution of infection and prevents spread.
• Other susceptible bacterial infections: may be used when the pathogen is proven susceptible.

• Moxifloxacin exerts its antibacterial activity by binding to the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV. Inhibition of these enzymes prevents the supercoiling and separation of bacterial DNA required for replication and transcription, leading to rapid bacterial cell death. The drug displays concentration‑dependent killing and a post‑antibiotic effect against Gram‑positive and Gram‑negative organisms, including atypical respiratory pathogens.

Moxifloxacin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate feeling of stomach upset, often transient.
• Diarrhea: loose stools that may be watery, usually self‑limiting.
• Headache: dull or throbbing pain, commonly reported during therapy.
• Rash: mild skin erythema or itching that typically resolves after discontinuation.

Serious or Rare Side Effects

• Tendon rupture: sudden tendon pain or rupture, especially in the Achilles tendon.
• QT interval prolongation: may lead to cardiac arrhythmias, requiring ECG monitoring.
• Severe allergic reaction (anaphylaxis): rapid onset of swelling, difficulty breathing, and hypotension.
• Clostridioides difficile‑associated colitis: severe diarrhea with abdominal cramping, requiring prompt medical attention.

Before prescribing Moxifloxacin, clinicians should consider several safety factors.

• Renal function: assess baseline kidney function and adjust therapy if impairment is present.
• Hepatic impairment: use with caution in patients with liver disease, monitoring liver enzymes.
• History of tendon disorders: avoid or closely monitor patients with prior tendon injury or tendon‑related conditions.
• QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances.
• Concomitant use of corticosteroids: increased risk of tendon rupture warrants careful observation.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Moxifloxacin can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid)

• Antacids containing magnesium or aluminum: reduce absorption of the drug, decreasing efficacy.
• Warfarin: may enhance anticoagulant effect, increasing bleeding risk.
• QT‑prolonging agents (e.g., quinidine, amiodarone): additive effect on cardiac repolarization, raising arrhythmia risk.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: may reduce hormonal effectiveness, consider alternative contraception.
• Corticosteroids: combined use can increase the likelihood of tendon injury.